Health Trials

Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine

ConditionsSphenopalatine BlockBOTOXChronic Migraine
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorCairo University

About this trial

This trial compares the efficacy and safety of sphenopalatine ganglion block (SPGB) and intramuscular BOTOX injection in chronic migraine.

Eligibility criteria

Qualifiers

Age 18 and 65 years.

Both sexes.

Chronic migraine. Chronic migraine, defined as headaches on ≥15 days per month for ≥3 months, of which ≥8 days meet criteria for migraine without aura or respond to migraine-specific treatment according to International Classification of Headache Disorders-3 Beta.

Disqualifiers

Patients with medication over use headache.

Bleeding disorders.

Abnormal neurological examination.

History of allergy to local anesthetics or BOTOX.

Trial design

Treatments tested in this trial

  • Sphenopalatine block
  • Botulinum Toxin Type A

Treatment groups

64 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Cairo University

Lead sponsor

Source ClinicalTrials.gov